{
  "links": "https://www.ycombinator.com/companies/valink-therapeutics",
  "name": "Valink Therapeutics",
  "headline": "Discovering bispecific antibody drug-conjugates (BsADC) against cancer",
  "batch": "W21",
  "description": "Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.",
  "activity_status": "Active",
  "website": "https://www.valinktx.com/",
  "founded_date": 2021.0,
  "team_size": 14.0,
  "location": "Boston",
  "group_partner": null,
  "group_partner_yc": null,
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:biotech; industry:therapeutics; industry:drug-discovery; location:boston",
  "founders": [
    {
      "name": "Arne Scheu, Founder",
      "description": "Rhodes Scholar & DPhil Biochemistry from the University of Oxford",
      "linkedin": "https://www.linkedin.com/in/arne-scheu-aa22b812b/"
    },
    {
      "name": "Irsyad Khairil, Founder",
      "description": "Pharma analyst with a background in protein engineering\nDPhil in Biochemistry from the University of Oxford",
      "linkedin": "https://www.linkedin.com/in/irsyad-khairil-bb216b9b/"
    }
  ],
  "status": true,
  "markdown": "raw_markdown='[![Valink Therapeutics logo](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6544ccf5a0a39011763738fb_Group%20252.svg)](https://www.valinktx.com/</>)\\nMenu\\nClose\\n[Home](https://www.valinktx.com/</>)[Technology](https://www.valinktx.com/</technology>)[Team](https://www.valinktx.com/</team>)[Careers](https://www.valinktx.com/</careers>)[News](https://www.valinktx.com/</news>)[Contact](https://www.valinktx.com/<#contact>)\\n# Targeted new cancer drugs, designed at unprecedented scale\\nWe revolutionise the discovery and development of bispecific antibody drug conjugates (bsADCs) to find the right treatment for any type of cancer.\\n[Get in Touch](https://www.valinktx.com/<#contact>)\\n[![A downwards-pointing arrow](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6537ef097c1d1c0c67b8de95_%E2%86%92.svg)](https://www.valinktx.com/<#our-solution>)\\nOur Solution\\n## The next generation of ADC development\\nBispecific ADCs (bsADCs) have the potential to revolutionise ADCs as dual targeting enables improved function and cell selectivity. Our technology allows us to quickly design and test new bsADCs with complex structures and diverse target and payload combinations.\\n[![a right-pointing arrow](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65313c9047debdd719b9a9bc_Group%20222.svg)Learn More About Our Technology](https://www.valinktx.com/</technology>)\\n### Rapid Design\\nThe discovery of bsADCs is held back by an inability to rapidly generate and screen new therapeutic candidates. Valink can build thousands of drug candidates in days from a variety of components, including antibody fragments and small molecules.\\n### Novel Drug Candidates\\nUsing our LiliumX™ discovery platform, we solve the fundamental challenges of bsADC discovery. This allows us to unlock unprecedented therapies in solid tumours and beyond. \\n### More Effective Treatments\\nWe target solid tumours with bispecific antibody-drug conjugates. By aiming at two markers at once, we can improve payload delivery and more accurately differentiate between malignant and healthy tissues.\\nNoteworthy\\n## Latest News\\n[![a right-pointing arrow](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65313c9047debdd719b9a9bc_Group%20222.svg)See More Stories](https://www.valinktx.com/</news>)\\n![a left-pointing arrow](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/653144f72d318829c3d73853_%E2%86%92.svg)\\n![a right-pointing arrow](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65314919c0841c0b7ac6820a_%E2%86%921.svg)\\n1\\n2\\n3\\n4\\n[![](https://cdn.prod.website-files.com/6531280ccc44add614f98108/6762a736787894a351fb6a17_image2.jpeg)Featured Article2024-12-18Press Release: \\u200dValink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board](https://www.valinktx.com/</news-updates/valink-therapeutics-appoints-biopharmaceutical-veteran-martin-d-williams-aschair-of-the-board-of-directors-and-names-scientific-advisory-board>)\\n[![](https://cdn.prod.website-files.com/6531280ccc44add614f98108/6697b725d8cc4772cd4d2652_IMG_7867%5B96%5D.jpeg)Featured Article2024-07-10Valink presents at Curious2024 Ignite Session](https://www.valinktx.com/</news-updates/valink-at-curious2024>)\\n[![](https://cdn.prod.website-files.com/6531280ccc44add614f98108/65440f22be320dd5d0f97d64_Arne%20and%20Irsyad%201-min.png)Featured Article2023-11-02Press Release: Rebrand, New Appointments & Fundraise](https://www.valinktx.com/</news-updates/press-release-rebrand-new-appointments-fundraise>)\\n[![](https://cdn.prod.website-files.com/6531280ccc44add614f98108/6544d48cbae1aa4704104266_World%20Bispecific%20Summit_Arne%20S%20Speaker%20Banner.png)Featured Article2023-10-02Arne Scheu, CEO of LiliumX, is presenting at the 14th World Bispecific Summit ](https://www.valinktx.com/</news-updates/arne-scheu-ceo-of-liliumx-is-presenting-at-the-14th-world-bispecific-summit>)\\n[![](https://cdn.prod.website-files.com/6531280ccc44add614f98108/6544d4d6cce957b65f6f66a6_2zfh%201.png)Featured Article2023-04-25LiliumX presenting at BioTrinity 2023](https://www.valinktx.com/</news-updates/liliumx-presenting-at-biotrinity-2023>)\\n[![](https://cdn.prod.website-files.com/6531280ccc44add614f98108/6531302a43693107c31bb198_62c6bd0a181cab385fe1d4e7_2.png)Featured Article2022-06-23LiliumX graduates from the Health stream of CDL](https://www.valinktx.com/</news-updates/liliumx-graduates-from-the-health-stream-of-cdl>)\\n[![](https://cdn.prod.website-files.com/6531280ccc44add614f98108/65312efb6d5fb799776e54e3_6167fbfbf18ae24111fea28c_Rectangle%2029-2.jpg)Featured Article2021-05-18Oxford University Innovation spins out LiliumX](https://www.valinktx.com/</news-updates/oxford-university-innovation-spins-out-liliumx>)\\n[![](https://cdn.prod.website-files.com/6531280ccc44add614f98108/65312ed0992c58989fde17e8_6167fbbdd51ce953888025a5_Rectangle%2029-1.jpg)Featured Article2021-03-24LiliumX graduates from Y Combinator startup accelerator in W21 batch](https://www.valinktx.com/</news-updates/liliumx-graduates-from-y-combinator-startup-accelerator-in-w21-batch>)\\nBacked By:\\n![RV Invest logo](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65440e2991a0aebf5cf2c910_RVI_logo_1C.svg)![Hoxton Venture Logo](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65313a5b6b895f2a851f7c13_hoxtonventures%201.svg)![](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6762bbb1e7fb6630bdd188b3_p53.svg)![SynBioVen logo](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65440d83bdcc4eacd112ac89_WEB-SBV%20BW%20Logo_Horiz_RGB_150%20DPI%201.png)![Magnet Venture Logo](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6544caf27ec10e56c66e77e1_Magnet%20Ventures%20logo.svg)![Metaplanet logo](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65440d018a4bc163fe545e16_Metaplanet-logo%201.png)![Acequia Capital Logo](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65313a5be9036b4a4e192a37_acequia_logo_lockup_blue%201.png)![Y Combinator logo](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65313a5b05b5264489d4db81_y-combinator-seeklogo.com%201.svg)![](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6762a1453225c9523d7687dc_oxonianventures%2B\\\\(3\\\\).png)![Oxford University & Oxford University Innovation Logos](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/653a7cad7bb9bb116f86439d_image%202blue%201.png)\\nContact Us\\nUnited States\\u200dValink Therapeutics Inc50 Milk Street, 16th floor,Boston, MA 02109\\nUnited Kingdom\\u200dValink Therapeutics LtdImperial I-Hub,84 Wood Lane,London, W12 0BZ \\n![a tick](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6538f54a8b35b08ee8a4506a_Group%20247.svg)\\nMessage sent successfully.\\n![a cross](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6538f54a356063cc6ea4dd34_Group%20248.svg)\\nOops, something happened. Please try again.\\nUnited Kingdom\\u200dValink Therapeutics LtdImperial I-Hub,84 Wood Lane,London,W12 0BZUnited States\\u200dValink Therapeutics Inc50 Milk St., 16th floor,Boston, MA 02109\\n[![Valink Therapeutics logo](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6544ccf5a0a39011763738fb_Group%20252.svg)](https://www.valinktx.com/<#>)[Home](https://www.valinktx.com/</>)[Technology](https://www.valinktx.com/</technology>)[News](https://www.valinktx.com/</news>)[Careers](https://www.valinktx.com/</careers>)[Team](https://www.valinktx.com/</team>)[Privacy Policy](https://www.valinktx.com/</privacy-policy>)\\n' markdown_with_citations='![Valink Therapeutics logo⟨1⟩](https://www.valinktx.com/</>)\\nMenu\\nClose\\nHome⟨2⟩Technology⟨3⟩Team⟨4⟩Careers⟨5⟩News⟨6⟩Contact⟨7⟩\\n# Targeted new cancer drugs, designed at unprecedented scale\\nWe revolutionise the discovery and development of bispecific antibody drug conjugates (bsADCs) to find the right treatment for any type of cancer.\\nGet in Touch⟨7⟩\\n![A downwards-pointing arrow⟨8⟩](https://www.valinktx.com/<#our-solution>)\\nOur Solution\\n## The next generation of ADC development\\nBispecific ADCs (bsADCs) have the potential to revolutionise ADCs as dual targeting enables improved function and cell selectivity. Our technology allows us to quickly design and test new bsADCs with complex structures and diverse target and payload combinations.\\n![a right-pointing arrow⟨9⟩Learn More About Our Technology](https://www.valinktx.com/</technology>)\\n### Rapid Design\\nThe discovery of bsADCs is held back by an inability to rapidly generate and screen new therapeutic candidates. Valink can build thousands of drug candidates in days from a variety of components, including antibody fragments and small molecules.\\n### Novel Drug Candidates\\nUsing our LiliumX™ discovery platform, we solve the fundamental challenges of bsADC discovery. This allows us to unlock unprecedented therapies in solid tumours and beyond. \\n### More Effective Treatments\\nWe target solid tumours with bispecific antibody-drug conjugates. By aiming at two markers at once, we can improve payload delivery and more accurately differentiate between malignant and healthy tissues.\\nNoteworthy\\n## Latest News\\n![a right-pointing arrow⟨9⟩See More Stories](https://www.valinktx.com/</news>)\\n![a left-pointing arrow⟨10⟩]\\n![a right-pointing arrow⟨11⟩]\\n1\\n2\\n3\\n4\\n![⟨12⟩Featured Article2024-12-18Press Release: \\u200dValink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board](https://www.valinktx.com/</news-updates/valink-therapeutics-appoints-biopharmaceutical-veteran-martin-d-williams-aschair-of-the-board-of-directors-and-names-scientific-advisory-board>)\\n![⟨13⟩Featured Article2024-07-10Valink presents at Curious2024 Ignite Session](https://www.valinktx.com/</news-updates/valink-at-curious2024>)\\n![⟨14⟩Featured Article2023-11-02Press Release: Rebrand, New Appointments & Fundraise](https://www.valinktx.com/</news-updates/press-release-rebrand-new-appointments-fundraise>)\\n![⟨15⟩Featured Article2023-10-02Arne Scheu, CEO of LiliumX, is presenting at the 14th World Bispecific Summit ](https://www.valinktx.com/</news-updates/arne-scheu-ceo-of-liliumx-is-presenting-at-the-14th-world-bispecific-summit>)\\n![⟨16⟩Featured Article2023-04-25LiliumX presenting at BioTrinity 2023](https://www.valinktx.com/</news-updates/liliumx-presenting-at-biotrinity-2023>)\\n![⟨17⟩Featured Article2022-06-23LiliumX graduates from the Health stream of CDL](https://www.valinktx.com/</news-updates/liliumx-graduates-from-the-health-stream-of-cdl>)\\n![⟨18⟩Featured Article2021-05-18Oxford University Innovation spins out LiliumX](https://www.valinktx.com/</news-updates/oxford-university-innovation-spins-out-liliumx>)\\n![⟨19⟩Featured Article2021-03-24LiliumX graduates from Y Combinator startup accelerator in W21 batch](https://www.valinktx.com/</news-updates/liliumx-graduates-from-y-combinator-startup-accelerator-in-w21-batch>)\\nBacked By:\\n![RV Invest logo⟨20⟩]![Hoxton Venture Logo⟨21⟩]![](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6762bbb1e7fb6630bdd188b3_p53.svg)![SynBioVen logo⟨22⟩]![Magnet Venture Logo⟨23⟩]![Metaplanet logo⟨24⟩]![Acequia Capital Logo⟨25⟩]![Y Combinator logo⟨26⟩]![](https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6762a1453225c9523d7687dc_oxonianventures%2B\\\\(3\\\\).png)![Oxford University & Oxford University Innovation Logos⟨27⟩]\\nContact Us\\nUnited States\\u200dValink Therapeutics Inc50 Milk Street, 16th floor,Boston, MA 02109\\nUnited Kingdom\\u200dValink Therapeutics LtdImperial I-Hub,84 Wood Lane,London, W12 0BZ \\n![a tick⟨28⟩]\\nMessage sent successfully.\\n![a cross⟨29⟩]\\nOops, something happened. Please try again.\\nUnited Kingdom\\u200dValink Therapeutics LtdImperial I-Hub,84 Wood Lane,London,W12 0BZUnited States\\u200dValink Therapeutics Inc50 Milk St., 16th floor,Boston, MA 02109\\n![Valink Therapeutics logo⟨1⟩](https://www.valinktx.com/<#>)Home⟨2⟩Technology⟨3⟩News⟨6⟩Careers⟨5⟩Team⟨4⟩Privacy Policy⟨30⟩\\n' references_markdown='\\n\\n## References\\n\\n⟨1⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6544ccf5a0a39011763738fb_Group%20252.svg: ![Valink Therapeutics logo\\n⟨2⟩ https://www.valinktx.com/</>: Home\\n⟨3⟩ https://www.valinktx.com/</technology>: Technology\\n⟨4⟩ https://www.valinktx.com/</team>: Team\\n⟨5⟩ https://www.valinktx.com/</careers>: Careers\\n⟨6⟩ https://www.valinktx.com/</news>: News\\n⟨7⟩ https://www.valinktx.com/<#contact>: Contact\\n⟨8⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6537ef097c1d1c0c67b8de95_%E2%86%92.svg: ![A downwards-pointing arrow\\n⟨9⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65313c9047debdd719b9a9bc_Group%20222.svg: ![a right-pointing arrow\\n⟨10⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/653144f72d318829c3d73853_%E2%86%92.svg: a left-pointing arrow\\n⟨11⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65314919c0841c0b7ac6820a_%E2%86%921.svg: a right-pointing arrow\\n⟨12⟩ https://cdn.prod.website-files.com/6531280ccc44add614f98108/6762a736787894a351fb6a17_image2.jpeg: ![\\n⟨13⟩ https://cdn.prod.website-files.com/6531280ccc44add614f98108/6697b725d8cc4772cd4d2652_IMG_7867%5B96%5D.jpeg: ![\\n⟨14⟩ https://cdn.prod.website-files.com/6531280ccc44add614f98108/65440f22be320dd5d0f97d64_Arne%20and%20Irsyad%201-min.png: ![\\n⟨15⟩ https://cdn.prod.website-files.com/6531280ccc44add614f98108/6544d48cbae1aa4704104266_World%20Bispecific%20Summit_Arne%20S%20Speaker%20Banner.png: ![\\n⟨16⟩ https://cdn.prod.website-files.com/6531280ccc44add614f98108/6544d4d6cce957b65f6f66a6_2zfh%201.png: ![\\n⟨17⟩ https://cdn.prod.website-files.com/6531280ccc44add614f98108/6531302a43693107c31bb198_62c6bd0a181cab385fe1d4e7_2.png: ![\\n⟨18⟩ https://cdn.prod.website-files.com/6531280ccc44add614f98108/65312efb6d5fb799776e54e3_6167fbfbf18ae24111fea28c_Rectangle%2029-2.jpg: ![\\n⟨19⟩ https://cdn.prod.website-files.com/6531280ccc44add614f98108/65312ed0992c58989fde17e8_6167fbbdd51ce953888025a5_Rectangle%2029-1.jpg: ![\\n⟨20⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65440e2991a0aebf5cf2c910_RVI_logo_1C.svg: RV Invest logo\\n⟨21⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65313a5b6b895f2a851f7c13_hoxtonventures%201.svg: Hoxton Venture Logo\\n⟨22⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65440d83bdcc4eacd112ac89_WEB-SBV%20BW%20Logo_Horiz_RGB_150%20DPI%201.png: SynBioVen logo\\n⟨23⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6544caf27ec10e56c66e77e1_Magnet%20Ventures%20logo.svg: Magnet Venture Logo\\n⟨24⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65440d018a4bc163fe545e16_Metaplanet-logo%201.png: Metaplanet logo\\n⟨25⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65313a5be9036b4a4e192a37_acequia_logo_lockup_blue%201.png: Acequia Capital Logo\\n⟨26⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/65313a5b05b5264489d4db81_y-combinator-seeklogo.com%201.svg: Y Combinator logo\\n⟨27⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/653a7cad7bb9bb116f86439d_image%202blue%201.png: Oxford University & Oxford University Innovation Logos\\n⟨28⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6538f54a8b35b08ee8a4506a_Group%20247.svg: a tick\\n⟨29⟩ https://cdn.prod.website-files.com/6531152978da3bf84b86c573/6538f54a356063cc6ea4dd34_Group%20248.svg: a cross\\n⟨30⟩ https://www.valinktx.com/</privacy-policy>: Privacy Policy\\n' fit_markdown='' fit_html=''",
  "generated_description": "**Valink Therapeutics: Innovating Cancer Treatment with Bispecific Antibody Drug Conjugates**\n\nFounded in 2021 as part of Y Combinator's Batch W21, Valink Therapeutics is a Boston-based biotech company focused on transforming cancer treatment through the development of bispecific antibody drug conjugates (bsADCs). Their mission is to discover more effective drugs targeted at solid tumors, areas of cancer biology that have been poorly addressed by existing immunotherapies.\n\n### What's Special About Valink?\n\nValink operates on a cutting-edge technology platform, LiliumX™, which allows for rapid design and testing of novel drug candidates. Unlike traditional methods that can take months to generate potential treatments, Valink's approach can produce thousands of drug candidates within days by incorporating multiple modifications to antibodies at once. This multitasking capability enhances their ability to create complex drug candidates that feature bi- and multispecificity, multivalency, and drug-conjugation—all in one streamlined process.\n\n### The Science Behind the Solutions\n\nThe bsADCs developed by Valink use a dual-targeting mechanism, enabling improved efficacy by more precisely delivering therapeutic payloads to malignant tissues while sparing healthy cells. This is particularly important in treating solid tumors where distinguishing between cancerous and healthy cells can be a significant challenge. By targeting two markers simultaneously, Valink's drugs hold the promise of being not just more effective but also safer.\n\n### The Team and Investors\n\nWith a compact team of 14 employees, Valink leverages the expertise and resources from prestigious backers, including RV Invest, Hoxton Ventures, and others, underscoring confidence in their innovative approach to drug discovery.\n\n### The Road Ahead\n\nValink Therapeutics is on a mission to unlock unprecedented therapies that will change the game in oncology. As they continue their work, we can look forward to new developments that could significantly improve outcomes for patients battling cancer.\n\nFor more details, visit their [website](https://www.valinktx.com/)."
}